All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Orgenesis Completes Koligo Acquisition and Gains Icellator Technology in Related Transaction

October 20, 2020
By Pharmaceutical Technology Editors
News
Article

Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.

On Oct. 19, 2020, Orgenesis, a biotechnology company specializing in cell and gene therapies, announced that it has completed its previously announced acquisition of Koligo Therapeutics, a regenerative medicine company, while also acquiring substantially all of the assets of Tissue Genesis, also a regenerative medicine company, and gaining Tissue Genesis’ Icellator technology for cell isolation.

Under the agreement, Orgenesis acquired all of the outstanding Koligo stock from Koligo shareholders for approximately $14.5 million in shares of Orgenesis common stock, which is valued at $7.00 per share, and an assumption of $1.9 million in liabilities (estimated to be substantially all of Koligo’s liabilities). Orgenesis acquired the assets of Tissue Genesis for an additional consideration of $500,000 in closing cash and future royalties.

With the Tissue Genesis acquisition, Orgenesis will now own the entire inventory of Icellator devices, related kits and reagents, a broad patent portfolio to protect the technology, registered trademarks, clinical data, and existing business relationships for commercial and development-stage use of the Icellator technology. The Icellator device is a point-of-care (POC) cell isolation technology. It rapidly recovers high yields of stromal and vascular cells (SVF) from adipose tissue, which has been recognized as a superior source of adult stem cells, to be used therapeutically.

The Icellator device is commercially available in Korea and the Bahamas where Orgenesis plans to continue commercial distribution. Clearance is expected in Japan for Icellator X in the first quarter of 2021, pending completion of manufacturing tests requested by the Japanese Pharmaceutics and Medical Devices Agency. In addition, Tissue Genesis has initiated several Phase I pilot trials of the Icellator system in the United States under FDA investigational device exemptions for use in erectile dysfunction, critical limb ischemia, tissue repair, and other therapeutic indications.

Orgenesis intends to potentially develop a broad range of POC autologous cell therapies with significantly reduced costs using the Icellator technology. The company plans to deploy these therapies across a growing POCare Network that includes leading hospitals and healthcare institutions.

“With the Koligo acquisition closed, we believe that we are making rapid progress on a number of fronts,” said Vered Caplan, CEO of Orgenesis, in a company press release. “Specifically, we plan to leverage the therapies and technologies from Koligo and Tissue Genesis across our POCare Platform. One of our first goals is to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well. Subject to FDA review and clearance of our IND [investigational new drug] application, we also look forward to commencing patient recruitment for a [Phase II] randomized clinical trial of KT-PC-301, an autologous clinical-development-stage cell therapy candidate for COVID-19-related Acute Respiratory Distress Syndrome, or ARDS.We plan to use the Icellator device to support scalable, cost-effective production of KT-PC-301. Additionally, Koligo’s development stage 3D-V bioprinting technology for the vascularization of autologous cells to create biodegradable and shelf-stable three-dimensional cell and tissue implants will be explored for diabetes and pancreatitis applications, with longer term applications for neural, liver, and other cell/tissue transplants also potentially explored.”

“The Icellator system is highly complementary to our POCare technology systems, as well as Koligo’s 3D-V bioprinting technology. Technologies such as these support our mission of improving the efficacy and lowering the costs of cell and gene therapies by delivering autologous cell therapies at the point of care through our global network of hospitals and healthcare institutions,” Caplan added in the press release.

Source: Orgenesis​

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content

A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

Related Content

A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.